Infusion of dimethylsulfoxide (DMSO) contained in cryopreserved and thawed hematopoietic stem cell (HSC) grafts is frequently associated with mild or moderate adverse reactions, and occasionally with more severe events including neurological symptoms. The severity of these complications is related to the amount of residual DMSO. We evaluated a recently available, closed, automated and 'cgmp (current good manufacturing practice) compliant' device (CytoMate TM ) for its ability to wash out DMSO at the expense of a limited loss of viable CD34 + cells. A total of 16 procedures were carried out with 39 blood HSC bags intended for destruction. Mean amounts of DMSO for each cellular product (one, two or three bags) were between 12.2 and 39.6 g before thawing; after the washing procedure, residual DMSO quantities were between 0.1 and 3.7 g. When set up to reproducibly allow for a more than 96% elimination of DMSO, processing of thawed cells with the CytoMate TM cell processor resulted in a mean recovery of viable total cells, CD34 + cells and lymphocyte subsets above 60%. We conclude that this simple and efficient washing technique is suitable for routine processing of HSC grafts. Clinical studies will demonstrate whether a reduction in the incidence of adverse effects associated with DMSO infusion is observed.
Introduction
Autologous hematopoietic stem cell (HSC) transplantation following high-dose cytotoxic therapy is used as a treatment for a number of malignant or nonmalignant blood diseases and solid tumors. Current treatment regimens require the cryopreservation and storage of HSC grafts for variable periods of time. Cryopreservation techniques most often use dimelthylsulfoxide (DMSO) as a cryoprotectant for optimal preservation of hematopoietic progenitor viability and function: cells can be injured by formation of ice crystals, and penetrating cryoprotectants such as DMSO provide cell protection by reducing the proportion of water incorporated into ice, and the extent of cellular dehydration. Infusion of residual DMSO following cryopreservation and thawing can cause dose-dependent cryoprotectant-related toxicity. Adverse reactions associated with the infusion of cryopreserved HSC have been widely described in HSC graft recipients. [1] [2] [3] [4] Reported complications range from mild (nausea, vomiting) to severe (acute renal failure and cardiac or pulmonary arrest). Most common toxicities associated with the infusion of cryopreserved HSC grafts include nausea, vomiting, abdominal pain and chills, 3, [5] [6] [7] a range of symptoms that are not totally abrogated with premedication. These complaints are quickly resolved after the completion of the procedure, and symptomatic treatments are used when necessary. Other complications, including variations in blood pressure, dyspnea or cardiac toxicities 8, 9 are also related to the infusion of cryoprotectant. A recent study 3 shows that the incidence of hypertension was 36% in a series of 75 patients receiving PBSC grafts, and that noncardiovascular complications occurred in 8% of patients. More unusual events are neurological. 10, 11 or cardiovascular. 12 Reports of neurological toxicity are infrequent: transient global amnesia and cerebral infarction have been described for three of 179 consecutive patients 11 receiving cryopreserved PBSC. This suggests that infusion of DMSO with cryopreserved stem cells may result in unusual but severe cerebrovascular ischemia secondary to acute neurological toxicity (none of these events occurred in the context of hypotension or brady-arrhythmias), as previously described in a nontransplant setting. 13 All these symptoms were coincident with the HSC infusion, and therefore are unlikely to result only from previous chemotherapy. Although many of the complications observed during HSC graft infusions can be attributed to DMSO, the influence of other factors, including cell debris and cytokines released by damaged or dead cells, should not be excluded; febrile reactions, for example, are mostly because of clumped and damaged white blood cells. Similarly, bradycardia and hemoglobinuria reported after bone marrow (BM) infusion are closely related to the red blood cell contamination of the cell therapy products, and consecutive release of hemoglobin, electrolytes and cell debris. 3 Some authors have suggested that damaged cells and lysis products, the low temperature of the infused product that may induce vagal responses, localized electrolyte abnormalities, or acute volume expansion leading to reflex bradycardia may all play a role in the pathogenesis of cardiovascular and other complications observed during infusion. 6, 8, 14 Finally, premedication with antihistaminics used to neutralize DMSO-induced histamine release may itself cause bradycardia. Therefore, the pathogenesis of many complications that occur during cryopreserved HSC graft infusion could be multifactorial.
Cryopreservation of selected CD34+ cells, and thus of small numbers of cells in a small volume has been proposed as one way to reduce the quantity of infused DMSO and associated symptoms. 15 However, CD34+ cell selection results in progenitor cell loss, and has thus far not proven its efficacy in reducing the relapse rate following high-dose chemotherapy and autologous hematopoietic cell transplantation. [16] [17] [18] Nowadays, the vast majority of transplantations are performed with unselected cell therapy products. Thus, removal of DMSO and cell lysis products by washing HSC grafts after thawing may reduce the severity of some complications, as described in a number of clinical studies. 19, 20 Conversely, HSC washing may result in a loss of hematopoietic progenitors; decrease the engraftment potential, and must therefore be used with caution. Current available techniques for washing out DMSO include slow dilution with an equal volume of an isotonic solution followed by manual centrifugation, 20 as described for cord blood units. 21 Bags can also be centrifuged with an automated blood cell processor, such as the Cobe 2991. 19, 22 In these procedures, the supernatant that contains part of the DMSO is discarded after the centrifugation step. Major inconveniences of centrifugation processes, either manually or automatically performed, are the low efficiency of DMSO elimination, and the release of cell lysis products.
Recently, a new bench-top device, CytoMatet (Baxter Oncology, Chicago, IL), has been made available. This processor is a user-definable system derived from the clinical cell selection device Isolext. 16, 17 It consists of a spinning membrane that ensures cell filtration against a counter-flow buffer circulation and is connected to different bags, in a completely closed system. We here report the results of a preclinical study, in which we evaluated the ability of this device to eliminate DMSO from cryopreserved aphereses, and the concurrent albeit limited loss of different cell types, including CD34 + progenitors.
Materials and methods

Study design
A total of 39 peripheral blood HSC bags, intended for destruction because of recipient death, were used in two different sets of experiments. As a first step, we compared the device efficiency with two different washing programs in order to find the most acceptable settings for DMSO elimination and recovery of viable CD34 + cells. We carried out seven washing procedures, each of them performed with two or three HSC bags, and two different settings for the processor. In a second set of experiments, we evaluated the reproducibility of DMSO removal. Nine washing procedures were performed with one, two or three HSC bags for each procedure, and fixed parameters for the processor.
HSC graft processing
Peripheral blood HSC were collected by apheresis from patients with various hematological or solid malignancies, mobilized with chemotherapy and/or rhG-CSF. Leukaphereses were performed using a Spectra blood cell separator (Gambro BCT, Lakewood, CO, USA). Peripheral blood HSC were processed within 24 h of the collection, and stored at +41C before cryopreservation. Owing to disease progression, these patients later died before being able to receive high-dose chemotherapy and autologous transplantation.
Excess plasma was removed from all apheresis products by centrifugation at 1400 rpm for 18 min. Concentrated stem and progenitor cells were slowly diluted at +41C with an equal volume of an ice-cold 4% human serum albumin (HSA) solution (Laboratoire Franc¸ais du Fractionnement et des Biotechnologies, Courtaboeuf, France) supplemented with 20% DMSO (Braun Medical SA, Boulogne, France), and transferred into freezing bags (Hemofreeze DF700, NPBI, The Netherlands) in a final volume of 120 ml. Freezing was performed using a liquid nitrogen controlledrate freezer (Digitcool, IMV CryoBioSystem, L'Aigle, France), and cells were stored in the vapor phase of liquid nitrogen.
After a short exposure to room temperature, thawing of HSC bags was performed in a 371C waterbath, until complete disappearance of ice crystals. Bags were stored on ice until all were thawed. When this step was completed, all HSC bags were immediately connected to the CytoMatet and slowly diluted with two volumes of a +41C PBS buffer (Baxter, Maurepas, France) supplemented with 5% Dextran 40 (Braun Medical SA, Boulogne, France), 5% ACD-A (Bioluz, Saint-Jean de Luz, France) and 1% HSA.
Setting up parameters for cell washing
The CytoMatet is a fully automated bench-top device that allows for a step-by-step user-definable programming. Cell washing and concentration are ensured by a spinning membrane connected to a filtered wash bag, a buffer bag and a waste bag. Four weight scales and probes allow for the monitoring of fluid transfers between the different bags.
The system features a sterile disposable set, including the spinning membrane and the wash bag, which creates a closed fluid path, and allows for cell processing in a cgmp (current good manufacturing practice) environment. The washing efficiency of the procedure is controlled and userdefinable by setting the 'residual fold reduction' parameter for each program in the microprocessor; a simple menudriven interface allows for programming of up to 100 custom procedures.
After connection of the HSC bags to the cell source line of the disposable set, cells are diluted twice with ice-cold PBS buffer, at first with 120 ml, at the rate of 20 ml/min, and then with 120 ml again, at the rate of 60 ml/min. Bags are gently shaken during this dilution step in order to avoid cell sedimentation. After this third dilution step, HSC are concentrated and washed by flowing through the spinning membrane (cells are drawn upwards for collection; the supernatant containing cell debris and DMSO is drawn through the membrane out and flows downwards). During the washing step, cells are transferred into a collection bag, and the washing bag and tubing are rinsed with 100 ml of buffer, in order to minimize cell loss. The efficiency and length of the washing step are defined by setting the logarithmic 'residual fold reduction' parameter from 1 (very low efficiency) up to 1000 (very high efficiency). The final volume, usually between 100 and 250 ml, is determined by the device microprocessor and depends on two parameters: the initial cell number and the 'residual fold reduction' value. The length of the washing procedure, including dilution, is of the order of 1 h.
Flow cytometry analyses
Cell product samples were obtained immediately before and after the washing procedure, and diluted to 50 Â l0 6 cells/ml or less by addition of a PBS solution, supplemented with 0.5% of human immunoglobulin. Absolute counts of CD34 + cells were determined, using the Stem-Kit numeration kit (Beckman-Coulter/Immunotech, Hialeah, FL, USA), 23 according to the manufacturer's instructions. This commercially available diagnostic kit includes the viability dye 7-amino actinomycin D (7-AAD) that allows for a quantitation of both viable and nonviable CD34 + cells. 
CD16
+ CD56 + cells were measured, using the single platform Multiset diagnostic kit (BDIS), according to the manufacturer's instructions. Data acquisitions and analyses were performed on a FACSCalibur four-color flow cytometer using the Multiset software (BDIS).
Clonogenic assays
A volume of 1 Â 10 4 and 4 Â 10 4 /ml unseparated cells were grown in methylcellulose H 4431 (Stem Cell Technologies, Vancouver, Canada) containing leukocyte conditioned medium (LCM) in triplicate, and incubated at 371C in a humidified atmosphere with 5% CO 2 . CFU-GM and BFU-E were counted 14 days after initiation of cultures, with an inverted microscope, according to published criteria. 25 CFU-C represent the sum of all types of observed colonies.
DMSO quantification
Evaluations of initial and residual quantities of DMSO were performed using capillary zone electrophoresis, as previously described. 26 Briefly, samples were taken before and after the washing procedure, and cryopreserved at À801C without further processing. Cryopreserved samples were thawed in a waterbath at 371C, centrifuged at 4000 rpm for 5 min, then diluted in 50 mM sodium borate buffer, 1 : 100 for samples collected before cell washing, 1 : 5 for samples collected after cell washing.
Results
Performances of two washing programs depend on the 'residual fold reduction'
As a first step, we took advantage of the user-definable programming of the device to define an optimal washing procedure, trying to simultaneously optimize DMSO elimination and viable CD34 + cell recovery. Considering that the main adjustable setting that influences the washing efficiency is the 'residual fold reduction', we have set up two washing programs, at 10 and 50 (these figures define a low washing efficiency, and were chosen in order to minimize cell loss). CD34 + cell counts were assessed immediately after thawing and after washing, and residual DMSO was quantified on final collection bags. All the procedures were performed with two or three HSC bags, in order to replicate as closely as possible clinical situations. Data on seven washing procedures, performed with a total of 20 HSC bags and a minimal residual fold reduction value at 10 (n ¼ 3) or 50 (n ¼ 4), are summarized in Table 1 . When the minimal residual fold was set at 10, the mean recovery of viable CD34 + cells was 99% (range: 86-108%), with a mean cell viability of 78% (range: 69-83%). Residual quantities of DMSO were between 0.9 and 3.7 g (which represents a mean reduction of 94.7% range: 91-100%). When the minimal residual fold was set at 50, the mean recovery of viable CD34 + cells was lower (69%, range: 58-80%), with a mean viability of 81% (range: 64-94%); however, residual quantities of DMSO were also lower, with no more than 0.4 g of DMSO in the final cell product (mean: 0.3 g): this represents a more than 99% (range: 99-100%) elimination of the cryoprotectant. Mean CD45 + cell recoveries were 77% (range: 62-107%) and 62% (range: 50-79%), with the residual fold reduction at 10 and 50, respectively.
Washing thawed cells with a residual fold reduction set at 50, reproducibly allows for the elimination of more than 96% of DMSO Based on previous results, we further assessed the device reproducibility when the residual fold reduction was set up at 50, a condition that maximizes DMSO elimination. The measured DMSO quantity after thawing was 23.2713.7 g, and the mean residual quantity after washing was 0.370.2 g. Thus, this washing program allows for a very efficient and reproducible elimination of DMSO (98.571.2%), with residual amounts lower than 2 mg/ml. This is at the expense of a cell loss that we further measured. After the washing procedure, mean viable CD45 + and CD34 + cell recoveries were 66% (when compared with values obtained before cryopreservation), with a post-wash viability of 72% (see Table 2 ). The mean CFU-GM recovery was 63%. These recoveries are comparable to those measured in the preceding set of experiments performed with the same residual fold reduction value (see Table 1 ). In addition, in this set of experiments, we assessed the recovery of accessory cells: recoveries were 80% for CD3 (Table 2 ). Sterility tests demonstrated that all final products were negative for aerobic and anaerobic contamination.
In addition to changes in the biochemical and cell characteristics of the product, washing with the Cytomatet resulted in a reduction in the final volume of the cell suspension; this may be advantageous for individuals that have deteriorated renal, pulmonary or cardiac function at the time when they undergo cell reinfusion.
Discussion
In cancer patients receiving high-dose chemotherapy with autologous stem and progenitor cell support, the infusion of cryopreserved cell therapy products, immediately after thawing at the bedside, and without any post-thaw processing other than filtration, remains nowadays a possible way to administer cell therapy products. Advantages associated with this procedure are the absence of additional, costly and time-consuming graft manipulation. In addition, it is arguable that minimal processing of the graft will result in minimal cell losses; however, the difficulty to carry out quality controls in these conditions preclude an accurate evaluation of viable and functional cell numbers that are truly reinfused to the patient. In addition, infusion of cryopreserved grafts cause minor to moderate toxicities in many recipients. Many patients complain of nausea, abdominal cramping, headache and chest tightness. As a result of the complex composition of cryopreserved HSC grafts, possible causes for these complications include the infusion of DMSO, damaged cells or cell debris. DMSO has been shown to induce histamine release, and the occurrence of flushing and pulmonary or abdominal complaints during infusion can be attributed to this mediator. Use of premedication may in part improve the toxicity resulting from histamine release. However, even when patients are premedicated with antihistaminic drugs and/or steroids, more serious complications can occur during cryopreserved HSC infusion, and appear to be directly related to the amount of injected DMSO. 3 Finally, the possibility that acute toxicity during graft infusion may affect the patient's ability to tolerate the subsequent transplant course cannot be excluded. Thus, improving patient comfort and safety during HSC infusion remains a concern for transplant teams.
In a preclinical study, we have evaluated the ability of a newly available biomedical device to wash out DMSO from thawed HSC grafts. The majority of the HSC grafts processed in our study consisted of two or three bags, mimicking clinical conditions for which washing out DMSO and concentrating HSC grafts will be most interesting. In order to evaluate closely the washing efficacy of this new technique, we have measured DMSO concentrations and absolute numbers of viable CD34 + cells before and after each washing procedure. Dosage of DMSO by capillary zone electrophoresis is a simple standardized method, ensuring rapid and precise determination of residual quantities. Moreover, this technique does not require any preliminary treatment of the sample, such as deproteinization or neutralization, allowing efficient and reproducible quantification. Using this technique, as well as the precise determination of the absolute number of viable CD34 + cells with a single-platform commercially available kit, we first selected settings for the washing program that ensure elimination of more than 95% DMSO with an acceptable recovery of total and CD34 + cells. It is noticeable however that increasing the DMSO reduction from approximately 95 to 99% would be associated with a significant additional loss of CD34 + cells (34%), a figure that is comparable to those observed during immunoselection of CD34 + cells: this needs to be weighted against potential clinical benefits associated with the increased reduction in residual DMSO. Additional experiments demonstrated that recovered cells remained viable and functional, as indicated by a viability of 72712% and a mean CFU-GM recovery of 63%. The loss for lymphocyte subsets-as phenotypically identified-was in the same range as the loss for CD34 + cells. With these settings, the procedure lasted approximately 1 h.
We conclude that this newly available, fully automated and closed cell processor is able to reproducibly eliminate DMSO, with an acceptable recovery of viable cells, including CD34 + progenitors. Washing cryopreserved and thawed cell therapy products places an additional burden on cell processing facilities; it however allows to reduce the time and working load for nursing and medical staff at the time of infusion. It allows for accurate biological evaluation of infused cell products, and thus better compliance with cgmp, this may also contribute to better define the dose-effect relation between the number of infused hematopoietic progenitors, and the time to neutrophil and platelet recovery after high-dose chemotherapy supported with autologous transplantation. Ultimately, clinical experience using washed HSC grafts will confirm whether patient morbidity is improved, and whether the cost of the procedure can be offset by clinical, quality of life and economical benefits.
Finally, other applications for this device may appear in a variety of cell therapy processes that require cell concentration or dilution.
